CELL INTELLIGENCE · 肿瘤细胞治疗研究

癌症之外的 CAR 工程化细胞治疗：重编程纤维化和免疫介导炎症

CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

工程化机械敏感 MSC 实现跨瘤种的合成放射诊疗靶向

Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types.

iPSC 来源 NK 细胞治疗诱导胶质母细胞瘤持久缓解并通过 B7-H3 靶向三特异性杀伤细胞衔接器克服耐药

iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.

FT538 在 77% 的 GSC 细胞系（NK 敏感和中等敏感）中表现出强效的杀肿瘤活性，在敏感模型中具有治愈潜力，并在体内显示出良好的持久性和耐受性。

一种用于通用药物递送和免疫治疗的可再生、可编程的 iPSC 来源血小板平台

A regenerative and programmable iPSC-derived platelet platform for universal drug delivery and immunotherapy.

IL-15 与 IL-21 协同作用提高 iPSC 来源的细胞毒性 T 细胞在实体瘤中的抗肿瘤疗效

IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.

生物工程化的 iPSC 来源人巨噬细胞，其血管紧张素转换酶 (ACE) 表达增高，可抑制实体肿瘤生长

Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth.

障碍与蓝图：胃肠道肿瘤 CAR-T 细胞治疗的下一代工程策略

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

实体瘤细胞治疗进展：欧洲视角与未来方向

Advances in cell therapy for solid tumours: European perspective and future directions.

工程化 BiTE 启发的 iPSC 外泌体以增强针对肺癌的 CAR-T 细胞治疗

Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer.

iPSC 来源 CAR-NK 细胞外囊泡治疗非小细胞肺癌：证据、工程化改造与转化障碍

iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.